By Stephen Priori
During the ISPOR 7th Annual European Congress, 24-26 October
2004, CCH Congress Centrum Hamburg, Hamburg, Germany, the scientific merit
exhibited in the contributed poster and podium presentations was recognized
with awards given by authors’ groups: general, new investigator and
students. This year the ISPOR Awards Committee evaluated approximately 64
podium presentations and over 400 poster presentations.
 |
 |
|
ISPOR
Contributed Poster Award Chair
Pedro Plans Rubio MD, MBA |
Karen
Rascati PhD, RPh with Best Student Podium
Winner Esmond Nwokeji |
ISPOR Best Contributed
Podium Presentation Award
Best General Podium Presentations
CV1
A HEALTH ECONOMIC EVALUATION OF ASPIRIN IN THE
PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
Lamotte M1, Annemans L1,
Evers T2, Kubin M3
1HEDM, Meise, Belgium; 2Bayer Vital GmbH, Leverkusen,
Germany; 3Bayer HealthCare, Wuppertal, Elberfeld, Germany
CV3
NURSING HOME RESIDENTS WITH STROKE: CHANGES IN MANAGEMENT LEVELS AND COSTS
OVER A SIX YEAR PERIOD
O'Brien JA,
Duran P, Caro JJ
Caro Research
Institute, Concord, MA, USA
DB3
DECREASED RATES OF MAJOR HYPOGLYCAEMIC EVENTS LEAD TO IMPROVED LONG TERM
COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS BIPHASIC HUMAN
INSULIN 30 IN TYPE 2 DIABETIC SUBJECTS IN DANISH, FINNISH, GERMAN,
NORWEGIAN, SPANISH, SWEDISH, AND UK SETTINGS
Lammert M1, Palmer AJ2, Roze S2, Minshall ME3,
Valentine WJ2
1Novo Nordisk A/S, Bagsvaerd, Denmark; 2CORE Center for
Outcomes Research, Binningen/Basel, Switzerland; 3CORE-USA,
Fishers, IN, USA
Best New Investigator Podium
Presentations
HP4
DRUG COSTS DEVELOPMENT AFTER PATENT EXPIRY IN
THE NETHERLANDS
Boersma C,
Bos JM, Klok RM, Postma MJ
Groningen
University Institute for Drug Exploration / University of Groningen Research
Institute of Pharmacy (GUIDE/GRIP), Groningen, Groningen, The Netherlands
QL7 VALIDATION OF A PATIENT-ADMINISTERED
QUESTIONNAIRE TO MEASURE THE SEVERITY OF LOWER URINARY TRACT SYMPTOMS IN
UNCOMPLICATED URINARY TRACT INFECTION: THE UTI SYMPTOM ASSESSMENT (USA)
QUESTIONNAIRE
Clayson DJ1, Wild DJ1, Keating K2,
Gondek K2
1Oxford Outcomes Ltd, Oxford, Oxon, UK; 2Bayer
HealthCare Pharmaceuticals, West Haven, CT, USA
UC4
VARIATION IN ADL FUNCTIONING WITHIN BARTHEL INDEX SCORES:IMPLICATIONS FOR
STROKE CLINICAL TRIALS AND PRACTICE
Banks JL1, Netten A2, Pollok J3,
Van de Peer L3, Salas M4
1Health Outcomes Strategy Group, Boston, MA, USA; 2University
of Kent at Canterbury, Canterbury, UK; 3Kent and Canterbury
Hospital, Canterbury, UK; 4Erasmus University Medical School,
Rotterdam, The Netherlands
Best Student Podium Presentations
HP3
PHARMACOECONOMIC EDUCATION AT NON-US COLLEGES OF
PHARMACY
Nwokeji ED, Rascati K
The
University of Texas at Austin, Austin, TX, USA
ISPOR Best Contributed
Poster Presentation
Best General Poster Presentations
PCN42 POOLING CLINICAL AND COST OUTCOMES: A CASE STUDY OF BEST SUPPORTIVE
CARE (BSC) IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC)
McAllister R1, Meddis D2, Jansen J1,
Ryan J1, Brown J2
1 MAPI Values Ltd, Bollington, Cheshire, UK; 2
AstraZeneca, Macclesfield, Cheshire, UK
PCV27 COST-EFFECTIVENESS OF BUPROPION IN SMOKING CESSATION IN FINLAND
Hahl J, Jormanainen V
GlaxoSmithKline Oy, Espoo, Finland
PES18 INTERPRETATION OF SCORES ON THE PSORIASIS INDEX OF QOL (PSORIQOL)
McKenna SP1, Meads DM1, Backhouse ME2
1
Galen Research, Manchester, UK; 2 Novartis Pharma AG, Basel,
Switzerland
Best New Investigator Poster
Presentations
PCN38 THE IMPACT OF SCREENING ADHERENCE ON MEDICAL EFFECTIVENESS
AND COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN GERMANY – A DECISION
ANALYSIS
Sroczynski G1, Voigt K2, Gibis B3,
Aidelsburger P4, Engel J5, Wasem J4,
Hillemanns P5, Hölzel D5, Goldie SJ6,
Siebert U1
1 Harvard Medical School, Boston, MA, USA; 2
Institute for Medical Informatics, Biostatistics, and Epidemiology,
University of Munich, Munich, Germany; 3 National Association of
Statutory Health Insurance Physicians, Berlin, Germany; 4
University of Duisburg-Essen, Duisburg-Essen, Germany; 5
University of Munich, Munich, Germany; 6 Harvard School of Public
Health, Boston, USA
PIN7 COST MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VS.
INTRAVENOUS AND ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS
INFECTION AND DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS
Rubio M1, Oppenheimer F2, Magaz S1,
Badia X1
1 Health Outcomes Research Europe, Barcelona, Barcelona, Spain;
2 Hospital Clinic I Provincial de Barcelona, Barcelona, Spain
PIN10 COST-EFFECTIVENESS OF EXPANDED HIV SCREENING OF BLOOD
DONATIONS IN GHANA
Van Hulst M1, Vermande J2, Sagoe K3,
Bos JM4, Postma MJ2
1 University of Groningen / Martini Hospital, Groningen,
Groningen, Netherlands; 2 University of Groningen, Groningen,
Groningen, Netherlands; 3 University of Ghana Medical School,
Accra, Accra, Ghana; 4 The Netherlands Vaccine Institute,
Bilthoven, Utrecht, Netherlands
Best Student Poster
Presentations
PCV47 DECISION ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE
MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE
Goehler A1, Dietz R1, Osterziel KJ1,
Siebert U2
1 Charitè Campus Virchow Klinikum, Berlin, Germany; 2
Harvard Medical School, Boston, MA, USA
PCV 63
OVER-ADHERENCE WITH ANTIHYPERTENSIVE MEDICATIONS AMONG CENTRAL TEXAS
VETERANS
Yang M, Vincze G, Barner JC
The University of Texas at Austin, Austin, TX, USA
PIN8 ECONOMIC EVALUATION OF HIV TREATMENTS: THE I.CO.N.A. COHORT STUDY
Merito M1, Baio G2, Bonaccorsi A3,
Pammolli F4, Riccaboni M4, Arici C5,
D’Arminio Monforte A6, Pezzotti P7, Corsini D8
1 Sant’Anna School of Advanced Studies, Pisa, PI, Italy; 2
University of Florence, Florence, Italy, Italy; 3 Sant’Anna
School of Advanced Studies, Italy; 4 University of Florence,
Italy; 5 Ospedali Riuniti – Bergamo, Italy; 6
University of Milan, Italy; 7 Istituto Superiore di Sanità,
Italy; 8 Informa srl, Italy
A
special thanks goes to all the judges, the ISPOR Annual European Congress
Awards Task Force Chairs as well as the ISPOR Awards Committee Chair who
volunteered their time and efforts in selecting the winners.
ISPOR ANNUAL EUROPEAN
CONGRESS AWARDS TASK FORCE CHAIRS:
Podium: Hans L. Severens, PhD, University Maastricht, Maastricht, The
Netherlands
Poster: Pedro Plans-Rubio, G.D. Public Health, Department de Sanitat,
Sant Pol, Spain
ISPOR JUDGES:
Linda Abetz MA, Mapi Values; Pamela Aidelsburger
MD, MPH, Alfred Krupp vor Bolther Foundation; Mikael Asmussen MSc,
Novo Nordisk A/S; Gilles Berdeaux PhD, MD, Laboratories Alcon France;
Ruth Brown MS, MEDTAP International; Catherine Brun, Novartis
Pharmaceuticals; F. Cankat Tulunay MS, HEDM; Miriam Cisternas MA,
Ovation Research; Hans-Peter Dauben MD, DIMDI; Karin
Ericsson MSc, Nycomed Group; Farah Farahati PhD, McMaster
University; Anna Filonenko BSc, Schering AG; Marlene Glydmark MCs,
MA, F. Hoffman-La Roche; Amin Haiderali MBA, MPH, AstraZeneca
Canada; Magdalini Hatzikou MBA, BSc, Boehringer Ingleheim Greece;
Klaus Hieke, NEOS Health AG; Barbara Hoegy MD, Aventis
Pharmaceuticals; John Hutton BSc, MEDTAP International; Micahel
Iskedjian MSc, RPh, PharmIdeas Research & Consulting Inc.; Chris
Knight MSc, BSc; RTI Health Solutions; Maria Kubin MD, MSc, Dayer
AG; Nelson Lam BSc, The Chinese University of Hong Kong; Louise
Longworth MSc, BSc, National Institute of Clinical Excellence; Eva
Lydick PhD, Lovelace Clinic Foundation; Farzana Malik, Medtronik;
Lorenzo Mantovani MSc, University of Milan; Monia Marchetti MD,
IRCCS Policlinico; Anne Marciniak MD, MBA, MSc, Pfizer Ltd.; Liviu
Niculescu MD, MPH, Pfizer; Judy O'Brien, Caro Research; David
Parry MSc, MA, Bristol Meyers Squibb; Chris Pashos PhD, Abt
Associates; Andrew Peterson PharmD, University of Sciences in
Philadelphia; James Piercy MSc, BSc, Adelphi Group; Olaf Pirk MD,
Fricke & Pirk GmbH; Valaikanya Plasai MPH,DrPH, Chulalanskornn
University; Marjolein Pompen PhD, Pfizer; Maarten Postma PhD,
Pfizer; Karen Rascati PhD, RPh, University of Texas; Bernhard
Reiter, Imadec University; Stephane Roze MSc, Core Center for
Outcomes; Antje Smala MSc, MERG, MERG; Herman Soto MSc,
AstraZeneca SA; Eva Tsakonas MSc, Aventis Pharmaceuticals; Timm
Volmer MD, MPH, Wyeth Pharmaceutical; Ruth Whittington MSc, BSc,
Rx Communications; Sorrel Wolowacz PhD, Research Triangle Institute;
Lillian Wang RPh, MSc, Boehringer Ingelheim Taiwan; Kim Wittrup-Jensen
PhD, MSc, Novo Nordisk A/S.
|
